Culture

Teaching artificial intelligence to adapt

image: From left: Terrence Sejnowski, Kay Tye and Ben Tsuda.

Image: 
Salk Institute

LA JOLLA--(December 16, 2020) Getting computers to "think" like humans is the holy grail of artificial intelligence, but human brains turn out to be tough acts to follow. The human brain is a master of applying previously learned knowledge to new situations and constantly refining what's been learned. This ability to be adaptive has been hard to replicate in machines.

Now, Salk researchers have used a computational model of brain activity to simulate this process more accurately than ever before. The new model mimics how the brain's prefrontal cortex uses a phenomenon known as "gating" to control the flow of information between different areas of neurons. It not only sheds light on the human brain, but could also inform the design of new artificial intelligence programs.

"If we can scale this model up to be used in more complex artificial intelligence systems, it might allow these systems to learn things faster or find new solutions to problems," says Terrence Sejnowski, head of Salk's Computational Neurobiology Laboratory and senior author of the new work, published on November 24, 2020, in Proceedings of the National Academy of Sciences.

The brains of humans and other mammals are known for their ability to quickly process stimuli--sights and sounds, for instance--and integrate any new information into things the brain already knows. This flexibility to apply knowledge to new situations and continuously learn over a lifetime has long been a goal of researchers designing machine learning programs or artificial brains. Historically, when a machine is taught to do one task, it's difficult for the machine to learn how to adapt that knowledge to a similar task; instead each related process has to be taught individually.

In the current study, Sejnowski's group designed a new computational modeling framework to replicate how neurons in the prefrontal cortex--the brain area responsible for decision-making and working memory--behave during a cognitive test known as the Wisconsin Card Sorting Test. In this task, participants have to sort cards by color, symbol or number--and constantly adapt their answers as the card-sorting rule changes. This test is used clinically to diagnose dementia and psychiatric illnesses but is also used by artificial intelligence researchers to gauge how well their computational models of the brain can replicate human behavior.

Previous models of the prefrontal cortex performed poorly on this task. The Sejnowski team's framework, however, integrated how neurons control the flow of information throughout the entire prefrontal cortex via gating, delegating different pieces of information to different subregions of the network. Gating was thought to be important at a small scale--in controlling the flow of information within small clusters of similar cells--but the idea had never been integrated into models through the whole network.

The new network not only performed as reliably as humans on the Wisconsin Card Sorting Task, but also mimicked the mistakes seen in some patients. When sections of the model were removed, the system showed the same errors seen in patients with prefrontal cortex damage, such as that caused by trauma or dementia.

"I think one of the most exciting parts of this is that, using this sort of modeling framework, we're getting a better idea of how the brain is organized," says Ben Tsuda, a Salk graduate student and first author of the new paper. "That has implications for both machine learning and gaining a better understanding of some of these diseases that affect the prefrontal cortex."

If researchers have a better understanding of how regions of the prefrontal cortex work together, he adds, that will help guide interventions to treat brain injury. It could suggest areas to target with deep brain stimulation, for instance.

"When you think about the ways in which the brain still surpasses state-of-the-art deep learning networks, one of those ways is versatility and generalizability across tasks with different rules," says study coauthor Kay Tye, a professor in Salk's Systems Neurobiology Laboratory and the Wylie Vale Chair. "In this new work, we show how gating of information can power our new and improved model of the prefrontal cortex."

The team next wants to scale up the network to perform more complex tasks than the card-sorting test and determine whether the network-wide gating gives the artificial prefrontal cortex a better working memory in all situations. If the new approach works under broad learning scenarios, they suspect that it will lead to improved artificial intelligence systems that can be more adaptable to new situations.

Credit: 
Salk Institute

TGen identifies gene that could explain disparity in COVID-19 effects

PHOENIX, Ariz. -- Dec. 15, 2020 -- The Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has identified a specific genetic target that could help explain the tremendous variation in how sick those infected with COVID-19 become.

The study results, recently published in the journal mSphere, describe a molecule made from DNA -- miR1307 -- as a potential dimmer switch that may influence the severity of the disease; why some infected with SARS-CoV-2, the virus that causes COVID-19, have mild or even no symptoms, while others become seriously ill or die.

Led by Nicholas Schork, Ph.D., a Distinguished Professor and Director of TGen's Quantitative Medicine and Systems Biology Division, researchers identified miR1307 by comparing the genetic elements of SARS-Cov-2 with seven other human coronaviruses, some of which merely cause common colds. In addition, they examined the genomes of coronavirus strains known to infect bats, pigs, pangolins, ferrets, civets and chickens.

"We pursued a systematic gene-by-gene comparative analysis, investigating how and to what extent the SARS-CoV-2 genome sequence differs from other well-characterized human and animal coronavirus genomes," Dr. Schork said. "Our study results will allow the development of models of how the virus and its hosts interact, enhancing our understanding of the disease-causing mechanisms of SARS-CoV-2 and how to exploit both viral and host therapeutic targets."

Study results suggest that miR1307 serves as a switch that turns various genes within the virus on or off, potentially making the disease more or less harmful to patients by regulating, for example, how fast or slow the virus replicates. In past studies, miR1307 has been found to affect the severity of several types of cancer, lung disease and the flu, specifically the H1N1 influenza virus that caused a 2009 pandemic. It was first discovered as a key regulatory agent in the Epstein-Barr virus, best known as the cause of infectious mononucleosis.

According to Dr. Schork, the study results also provide the basis for additional investigations, such as designing vaccines based on proteins or RNA, developing specific genetic markers for community disease monitoring, and tracing COVID-19 from one species to another.

Credit: 
The Translational Genomics Research Institute

Vaping could nearly triple the chance of smoking in teens

COLUMBUS, Ohio -- A new study offers strong evidence that kids who use e-cigarettes are more likely to take up smoking or smokeless tobacco, researchers say.

Teen boys who vaped were almost three times as likely to start smoking as other teen boys with similar risk profiles and more than two times as likely to try smokeless tobacco, the study from The Ohio State University found. The research was published online this week in the journal Addictive Behaviors.

Unlike most previous research suggesting a link between vaping and tobacco, this study didn't simply follow young people over time to make a connection between the two behaviors. That's important, because some have questioned the validity of those longitudinal studies, arguing that kids who took up smoking might have done so whether they vaped or not, said lead researcher Brittney Keller-Hamilton, who completed the study as a graduate student and program manager in Ohio State's College of Public Health.

"For an ideal study, from a purely scientific perspective, we'd give everybody an e-cigarette, follow them for a few years and see if they start smoking, then rewind the clock and don't give them an e-cigarette. Or we'd randomly assign kids to vape or not to vape," she said. "We can't do either of those things, obviously."

So they looked to an advanced statistical approach -- "causal inference" -- in which they compared users and non-users of e-cigarettes who started the study with similar known risk factors for vaping based on a variety of factors, including alcohol use, marijuana use, impulsivity and their parents' education levels and tobacco history.

"We identified two groups of young people who were equally likely to start vaping based on a number of factors, and then we compared the outcomes over the course of the study. We found that e-cigarette users were 2.7 times as likely to try smoking," said Keller-Hamilton, who currently works as a research scientist in the Center for Tobacco Research at Ohio State's Comprehensive Cancer Center.

Study co-author Bo Lu, a biostatistics professor at Ohio State, said the approach leads to more robust scientific findings, and brings researchers closer to a true estimate of the causal effect of vaping on cigarette smoking in young people.

"I hope that our findings provide policymakers and others stronger evidence of the connection between e-cigarette use and tobacco use and that this will lead to positive impacts on more thoughtful designs in health policy research," Lu said.

This research is part of the Buckeye Teen Health Study, which followed more than 1,200 boys from urban Franklin County and nine rural Appalachian counties in Ohio for two years. They were 11 to 16 years old when they entered the study.

The new findings support continued efforts to restrict access to tobacco products to those 21 and older and actions to discourage vaping among kids, including measures that make e-cigarettes harder to obtain and less appealing, Keller-Hamilton said.

The data for this study was collected before federal restrictions were imposed on certain types of vaping products that appeal to young people, including those with flavors.

"But for all of these policies there are loopholes that the tobacco industry quickly identifies and works around, so it is important to remain vigilant in seeking strategies and policies to prevent teens from starting habits that pose a threat to their health, particularly when they serve as a stepping-stone to more harmful tobacco products," Keller-Hamilton said.

Credit: 
Ohio State University

CAN risk in diabetes reduced with intensive control of blood glucose and blood pressure

BOSTON - (December 16, 2020) - Intensive interventions to reduce blood glucose and blood pressure levels in type 2 diabetes reduce the risk of developing cardiovascular autonomic neuropathy (CAN), a frequent but underdiagnosed complication of diabetes that can be life-threatening.

In a study led by Alessandro Doria, MD, PhD, MPH, from the Joslin Diabetes Center and Harvard Medical School, and Rodica Pop Busui, MD, PhD, of the University of Michigan, published online in Diabetes Care, researchers found that intensive glycemic control reduced CAN risk by 17%, while intensive blood pressure control reduced risks by 22%.

They also found that intensive control of blood glucose was more effective in individuals with no history of cardiovascular disease (CVD) and that blood pressure lowering was more effective in individuals older than 65 years, suggesting that some degree of personalization of risk reduction might be possible.

They add that any benefits with the approach should be weighed against risks and costs, particularly because excess mortality has been observed in a trial, following intensification of treatment for glycemia.

The analysis focuses on the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which originally investigated the effects of intensive glycemic, blood pressure control and lipid interventions on cardiovascular events in individuals with type 2 diabetes and high CVD risks.

For their analysis the authors included participants that had an evaluation for CAN at baseline and at least one more assessment after randomization (~7000 individuals). Specifically, they looked at the effects on CAN of intensive glucose treatment, intensive blood pressure treatment and fenofibrate (a lipid lowering agent), compared to standard treatments.

None of the interventions (intensive and standard care) involved the newer drugs class of SGLT2 inhibitors and only few participants received GLP1-receptor agonists towards the end of trial, as the overall trial ran from early 2001 through to 2010 when these drugs were not widely used in clinical practice. The average follow-up was about five years.

They found that intensive treatment to reduce HbA1c (a measure of blood glucose levels) to near normal levels resulted in a 17% reduced risk for CAN (odds ratio: 0.83; confidence interval 0.74-0.93; p=0.002) compared to standard treatment, and that was after adjusting the risk model for a very broad spectrum of confounding factors, including all traditional CAN and cardiovascular disease risk factors.

The same direction of effect was evident for the intensive treatment of raised blood pressure. That approach resulted in a 22% reduced risk for CAN compared to standard treatment approaches (odds ratio: 0.78; CI 0.65-0.92; p=0.004) after adjusting for confounding factors. Treatment with fenofibrate and a statin compared to placebo and a statin was not as successful, with no significant difference between the interventions.

Additional analyses based on subgrouping showed that the protective effects of intensive treatment of glycemia on CAN risk was only found in individuals without a history of cardiovascular disease events but not in individuals with such a history. Blood pressure interventions was especially evident in older adults over the age of 65 years where CAN risk was reduced by 34%.

Notably, intensive glycemic control applied on top of intensive blood pressure control did not appear to reduce CAN risk more than intensive blood pressure lowering on its own. Taken together, the authors suggest these observations point towards the possible personalization of risk reduction strategies, but that more research will be needed to confirm the usefulness of these approaches.

While concluding that intensive glycemic and blood pressure control is likely to benefit patients in terms of CAN risk reduction, they do urge caution with respect to risks and costs. This is particularly from the perspective that the original ACCORD trial showed that after three and half years of follow-up, intensive glucose-lowering did result in reduced non-fatal cardiovascular events but paradoxically also an increase in overall mortality.

Commenting further on the research, senior co-author Dr Alessandro Doria said:

"Based on previous smaller studies, we thought that intensive glycemic and blood pressure control would probably work, but these results provide us with definitive proof that these treatments can be used to prevent this serious complication of diabetes."

Co-author Prof Rodica Pop Busui added:

"These findings have high clinical care relevance, as we have previously demonstrated that CAN, even in earlier stages, independently predicts cardiovascular and all-cause mortality in type 2 diabetes, and major cardiovascular events and heart failure in type 1 diabetes."

Credit: 
Joslin Diabetes Center

COVID-19 spread increases when UV levels decrease

Natural variations in ultraviolet radiation influence the spread of COVID-19, but the influence is modest compared to preventive measures such as physical distancing, mask wearing, and quarantine, according to new research from Harvard University.

"Understanding the potential seasonality of COVID-19 transmission could help inform our response to the pandemic in the coming months," said Jonathan Proctor, a postdoctoral fellow at the Harvard Data Science Initiative and the Harvard Center for the Environment. "These findings suggest that the incidence of COVID-19 may have a seasonal pattern, spreading faster in the winter when it's darker than in the summer."

Analyzing daily COVID-19 and weather data from over 3,000 administrative regions in more than 170 countries, Proctor, together with co-authors Peter Huybers, also at Harvard University, Tamma Carleton and Kyle Meng from the University of California Santa Barbara and Jules Cornetet at France's École Normale Supérieure Paris-Saclay, found that the spread of COVID-19 through a population tended to be lower in the weeks following higher UV exposure. Findings were published in the Proceedings of the National Academy of Sciences.

The seasonality of COVID-19 has been a mystery since the disease first emerged one year ago, though there have been some clues that UV could play a role. Related species of coronaviruses such as SARS and MERS were found to be sensitive to UV radiation and recent laboratory studies show that UV inactivates SARS-CoV-2, the virus that causes COVID-19, on surfaces.

Attempts to understand the influence of UV in the real world, however, have been limited by scarce data and the difficulty of isolating climate variables from other drivers of transmission. To test for an environmental signal within the noise of the pandemic, the team compiled and cleaned data from statistical agencies around the world. To avoid potentially confounding factors that differ across regions, such as healthcare infrastructure or population density, the team examined how transmission within a particular population changed according to variations in sunlight, temperature, precipitation and humidity experienced by that same population.

"We basically ask whether daily fluctuations in environmental conditions experienced by a population affect new COVID-19 cases up to two weeks later," Meng explained.

The researchers diagnosed the relationship between UV and COVID-19 using data from the beginning of the pandemic and then used that relationship to simulate how seasonal changes might influence the spread of COVID-19. They found that changes in UV between winter and summer led to a 7-percentage point decrease in the COVID-19 growth rate on average across the Northern Hemisphere, which is about half the average daily growth rate at the beginning of the pandemic. While this research shows that COVID-19 exhibits a seasonal pattern due to changes in UV, the full seasonality of COVID-19 remains unclear because of uncertain influences from other environmental factors such as temperature and humidity.

"We are confident of the UV effect, but this is only one piece of the full seasonality picture," Carleton said.

The team noted that environmental influences are just one of many determinants of COVID-19 transmission, and that the estimated effects of UV seasonality in the Northern and Southern Hemispheres are a fraction of the size of previously estimated effects of anti-contagion policies including quarantines and travel bans.

"As we saw in the U.S. this summer, UV exposure alone is unlikely to stop the spread of the virus without strong social distancing policies," said Proctor. "Regardless of the weather, additional measures appear to be necessary to substantially slow the spread."

The team analyzed the data in multiple ways and consistently found that the higher the UV, the lower the spread of COVID-19, but it remains unclear what mechanism is driving that effect. It may be that UV destroys the virus on surfaces or in aerosols, or that on sunny days people go outside more where there is less transmission. It is even possible that UV reduces susceptibility to COVID-19 by stimulating production of vitamin D and boosting the immune system.

"There's still so much that we don't know about how environmental factors both directly and indirectly, though human behavior, influence the spread of the virus," said Huybers. "But a better understanding of the environmental influences on COVID-19 could allow for seasonal adjustment of containment policies and may help inform vaccination strategies.

Credit: 
Harvard John A. Paulson School of Engineering and Applied Sciences

Oral hormone therapy shown to significantly alter metabolome of menopausal women

Groundbreaking research led by a team of scientists including a University of Massachusetts Amherst biostatistician shows that oral hormone therapy (HT) significantly alters the metabolome of postmenopausal women. This finding, which examined blood specimens from the landmark Women's Health Initiative (WHI) study, may help explain the disease risks and protective effects associated with different regimens of hormone therapy.

"This is the first analysis of the metabolomic effects of hormone therapy conducted within the framework of a randomized clinical trial," says Raji Balasubramanian, associate professor in the School of Public Health and Health Sciences, whose research connects biostatistics, molecular epidemiology and women's health.

Balasubramanian, in collaboration with Dr. Kathryn M. Rexrode at Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, and colleagues at the Broad Institute of Harvard and MIT, Harvard's T.H. Chan School of Public Health, Brown University and several institutions in Spain, wanted to study whether hormone therapy alters the universe of small molecule metabolites. "The answer was a resounding yes," says Balasubramanian, lead author of the paper published in Circulation: Genomic and Precision Medicine.

The WHI's hormone therapy trials in the 1990s examined the effects on coronary heart disease (CHD), breast cancer and other conditions of two hormone therapies - estrogen alone and a combination of estrogen and progestin. The combination therapy was found to significantly increase CHD risk by 29%; estrogen alone was found to decrease CHD risk by 9%, although this effect was not statistically significant.

"Our focus was on cardiovascular disease and understanding at a molecular level why these two hormone therapy regimens had disparate effects in regard to cardiovascular disease," Balasubramanian says.

Using liquid chromatography mass spectrometry (LC-MS) techniques, researchers at the Broad Institute measured 481 metabolites in blood specimens from the WHI hormone therapy trial participants: 503 from women in the estrogen-only group, half of whom were on placebo; and 431 in the estrogen plus progestin group, with half on placebo. The research team recorded measurements obtained right before hormone therapy began and one year later, when the women were still on active treatment or placebo.

The findings revealed "profound changes in the metabolome, spanning a wide range of classes including lipids, amino acids and other small molecule metabolites," Balasubramanian says. In fact, 62% of metabolites were significantly changed with estrogen-alone therapy, and 52% with estrogen plus progestin.

While most of the changes in metabolites were consistent with each type of hormone therapy, 22 metabolites were identified that had discordant effects. Twelve of those were associated with CHD risk in an evaluation of an independent WHI dataset.

With estrogen-alone treatment, the changes in all 12 metabolites provided a protective CHD effect. With estrogen plus progestin, 11 metabolites were unchanged. The amino acid lysine was significantly altered by both hormone therapies, but in the opposite direction. Estrogen-alone therapy increased lysine levels, providing a protective effect, and estrogen plus progestin decreased lysine levels, elevating CHD risk.

"Getting a handle on what subset of metabolites had differential changes between the two drugs related to cardiovascular diseases might point to the molecular underpinnings of the difference in risk between the two treatments," Balasubramanian explains.

UMass Amherst 2020 graduate Ryan Sheehan contributed to the data analytic aspects of the study and continues to work in Balasubramanian's lab as a research associate. Taking part in the study was "the best experience a student could have," he says. "Not only was I able to contribute my own skills and knowledge to this important paper, but also I was able to learn so much about the processes that go on with professional research. The amount of time and attention to detail that went into each step is something I will try to mimic in my own work as I progress in my professional career."

The study also lays the groundwork for identifying other hormone therapy-related metabolomic changes in a broader age group of women and how those changes are associated with differential risks for other health conditions, such as breast cancer, depending on the hormone regimen.

"We're excited to contribute to advancing research in women's health," Balasubramanian says.

Credit: 
University of Massachusetts Amherst

<i>Harvard Data Science Review</i> explores reproducibility and replicability in science

CAMBRIDGE, MA--December 16, 2020--In 2019, the National Academies of Science, Engineering, and Medicine (NASEM) published a consensus report for the US Congress--Reproducibility and Replicability in Science--which addressed a major methodological crisis in the sciences: The fact that many experiments and results are difficult or impossible to reproduce. The conversation about this report and this vital topic continues in a special, twelve-article feature in issue 2:4 of the Harvard Data Science Review (HDSR), publishing today.

Growing awareness of the replication crisis has rocked the fields of medicine and psychology, in particular, where famous experiments and influential findings have been cast into doubt. But these issues affect researchers in a wide range of disciplines--from economics to particle physics to climate science--and addressing them requires an interdisciplinary approach.

"The overall aim of reproducibility and replicability is to ensure that our research findings are reliable," states HDSR Editor-in-Chief Xiao-li Meng in his editorial. "Reliability does not imply absolute truth--which is an epistemologically debatable notion to start with--but it does require that our findings are reasonably robust to the relevant data or methods we employ."

"Designing sound replication studies requires a host of data science skills, from statistical designs to causal inference to signal-noise separation, that are simultaneously tailored by and aimed at substantive understanding," Meng continues.

Guest edited by Victoria Stodden (University of Illinois, Urbana-Champaign), the special theme collection presents research and commentary from an interdisciplinary group of scholars and professionals. Articles include:

Interview with Reproducibility and Replicability in Science Committee Chair Harvey V. Fineberg, President of the Gordon and Betty Moore Foundation and HDSR guest editor, Victoria Stodden, committee member by HDSR Editor-in-Chief Xiao-Li Meng

"Self-Correction by Design" by Marcia McNutt, President of NAS

"Leveraging the National Academies 'Reproducibility and Replication in Science' Report to Advance Reproducibility in Publishing" by Manish Parasha, Assistant Director for Strategic Computing at the White House Office of Science and Technology Policy, and Director of the Office of Advanced Cyberinfrastructure at the National Science Foundation

"Toward Reproducible and Extensible Research: from Values to Action" by Aleksandrina Goeva (Broad Institute), Sara Stoudt (Smith College), Ana Trisovic (Harvard University)

"Reproducibility and Replicability in Economics" by Lars Vilhuber (Cornell University)

"Reproducibility and Replicability in Science, A Metrology Perspective" by Anne L. Plant (National Institute of Standards and Technology) and Robert J. Hanisch (National Institute of Standards and Technology)

"Perspectives on Data Reproducibility and Replicability in Paleoclimate and Climate Science" by Rosemary T. Bush (Northwestern University), Andrea Dutton (University of Wisconsin, Madison), Michael N. Evans (University of Maryland, College Park), Rich Loft (National Center for Atmospheric Research), and Gavin A. Schmidt (National Aeronautics and Space Administration)

"Science Communication in the Context of Reproducibility and Replicability: How Non-Scientists Navigate Scientific Uncertainty" by Emily Howell (University of Wisconsin-Madison)

"Learning Lessons on Reproducibility and Replicability in Large Scale Genome-Wide Association Studies" by Xihong Lin (Harvard University)

"Selective Inference: The Silent Killer of Replicability" by Yoav Benjamini (Tel Aviv University)

"Trust but Verify: How to Leverage Policies, Workflows, and Infrastructure to Ensure Computational Reproducibility in Publication" by Craig Willis (University of Illinois at Urbana-Champaign) and Victoria Stodden

"Reproducibility and Replication of Experimental Particle Physics Results" by Thomas R. Junk (Fermi National Accelerator Laboratory) and Louis Lyons (University of Oxford, Emeritus)

The editors hope to take advantage of the collaborative features available on the open-source publishing platform, PubPub, where HDSR is hosted. Readers around the world can freely read, annotate, and comment on the essays--continuing this important conversation.

 

Credit: 
The MIT Press

A no-meat diet everywhere will not solve the climate crisis

image: Livestock being fed improved forages in Tanzania.

Image: 
Georgina Smith / International Center for Tropical Agriculture

People in industrialized regions like the United States of America or Europe are generally urged to eat less meat and animal-source foods as part of a healthier and lower-emissions diet. But such recommendations are not universal solutions in low- or middle-income countries, where livestock are critical to incomes and diets, argue scientists in recently published research in Environmental Research Letters.

"Conclusions drawn in widely publicized reports argue that a main solution to the climate and human health crisis globally is to eat no or little meat but they are biased towards industrialized, Western systems," said Birthe Paul, the lead author and environmental scientist at the Alliance of Bioversity International and the International Center for Tropical Agriculture (CIAT).

For example, of all scientific literature on livestock published since 1945, only 13% covers Africa. Yet Africa is home to 20%, 27% and 32% of global cattle, sheep and goat populations. Eight of the world's top ten institutes publishing livestock research are in the United States, France, the United Kingdom and the Netherlands. Only two, including the International Livestock Research Institute (ILRI), are headquartered in Africa, where the livestock sector is the backbone of the economy and where little data is available.

Authors further argue that a singular focus on negative livestock-related environmental impacts ignores the critical but more positive role livestock play in ecosystem services, income and asset provision or insurance in low- and middle-income countries. It also overlooks more systemic questions about how animals are raised.

"Mixed systems in low- and middle-income countries, where animal production is fully linked with crop production, can actually be more environmentally sustainable," said An Notenbaert, from the Alliance of Bioversity International and CIAT. "In sub-Saharan Africa, manure is a nutrient resource which maintains soil health and crop productivity; while in Europe, huge amounts of manure made available through industrialized livestock production are overfertilizing agricultural land and causing environmental problems."

Across Africa's savanna, pastoralists pen their herds at night, a practice shown to increase nutrient diversity and biodiversity hotspots, enriching the landscape. Feed production may also be more local, whereas, in industrialized systems, it is mostly imported. In Brazil, soybean - a major driver of deforestation in the Amazon - is made into concentrate and exported to feed animals in places like Vietnam as well as Europe.

"Meat production itself is not the problem. Like any food, when it is mass-produced, intensified and commercialized, the impact on our environment is multiplied," said Polly Ericksen, Program Leader of Sustainable Livestock Systems at the International Livestock Research Institute. "Eliminating meat from our diet is not going to solve that problem. While advocating a lower-meat diet makes sense in industrialized systems, the solution is not a blanket climate solution, and does not apply everywhere."

According to the Food and Agriculture Organization, meat consumption in sub-Saharan Africa will be as low as an average of 12.9 kilograms per person by 2028, due to low incomes and climate-induced heat-stress in animals among other factors, with human health implications like malnutrition and stunting. By comparison, meat consumption in the United States is expected to rise above 100 kilograms per person - the highest in the world.

Authors acknowledge that livestock systems are known to be a major source of atmospheric greenhouse gases. But more data is needed for low- and middle-income countries to develop national mitigation strategies. They also urge a need to look beyond making animals more productive and toward resource-efficient and environmental systems that actively reduce emissions from agriculture.

The authors point to a range of higher-impact environmental solutions. Among them, improved animal feed so animals emit less greenhouse gases like methane per kilogram of milk or meat. Better managed grazing land, and mixing crop and livestock where manure is plowed back into the soil, can benefit both farmers and the environment.

"Better decisions about how to reduce global greenhouse gas emissions from livestock and agriculture in low- and middle-income countries can only be driven by better data," said Klaus Butterbach-Bahl, at the Institute of Meteorology and Climate Research, Atmospheric Environmental Research (IMK-IFU) Karlsruhe Institute of Technology (KIT) and ILRI.

"For that, we need more - and not less - locally-adapted and multi-disciplinary research together with local people in low- and middle-income countries, on sustainable livestock development, with all the supporting financial incentives, policies and capacity in place to intensify livestock production in a more sustainable way, on a bigger scale."

Credit: 
The Alliance of Bioversity International and the International Center for Tropical Agriculture

How the spread of the internet is changing migration

The spread of the Internet is shaping migration in profound ways. A McGill-led study of over 150 countries links Internet penetration with migration intentions and behaviours, suggesting that digital connectivity plays a key role in migration decisions and actively supports the migration process.

Countries with higher proportions of Internet users tend to have more people who are willing to emigrate. At the individual level, the association between Internet use and intention to migrate is stronger among women and those with less education. The same result was found for economic migrants compared to political migrants, according to the team of international researchers from McGill University, University of Oxford, University of Calabria, and Bocconi University.

"The digital revolution brought about by the advent of the Internet has transformed our societies, economies, and way of life. Migration is no exception in this revolution," says co-author Luca Maria Pesando, an Assistant Professor in the Department of Sociology and Centre on Population Dynamics at McGill University.

In the study, published in Population and Development Review, the researchers tracked Internet use and migration pathways with data from the World Bank, the International Telecommunication Union, the Global Peace Index, the Arab Barometer, and the Gallup World Poll, an international survey of citizens across 160 countries.

Their findings underscore the importance of the Internet as an informational channel for migrants who leave their country in search of better opportunities. Unlike political migrants, who might be pushed, for example, by the sudden explosion of a civil conflict, economic migrants' decisions are more likely to benefit from access to information provided by the Internet, and more likely to be shaped by aspirations of brighter futures in their destination countries.

"The Internet not only gives us access to more information; it allows us to easily compare ourselves to others living in other - often wealthier - countries through social media," says Pesando.

Case study of Italy

Looking at migration data in Italy - a country that has witnessed sizeable increases in migrant inflows over the past two decades - the researchers found a strong correlation between Internet use in migrants' countries of origin, and the presence of people from that country in the Italian population register in the following year. Tracking migrants including asylum seekers and refugees passing through the Sant'Anna immigration Centre in Calabria, the researchers also found a link between migrants' digital skills and knowledge of the Internet and voluntary departure from the Centre in search of better economic opportunities.

"Our findings contribute to the growing research on digital demography, where Internet-generated data or digital breadcrumbs are used to study migration and other demographic phenomena," says Pesando. "Our work suggests that the Internet acts not just as an instrument to observe migration behaviors, but indeed actively supports the migration process."

As next steps, the research team, which includes Francesco Billari of Bocconi University and Ridhi Kashyap and Valentina Rotondi of University of Oxford, will explore how digital technology and connectivity affect social development outcomes, ranging from women's empowerment to reproductive health and children's wellbeing across generations.

Credit: 
McGill University

Potential treatment approach kills lymphoma while sparing healthy cells

image: A heavy layer of glycans, seen here in green, cover immune cells and provide a way to target cancer-specific markers in the body.

Image: 
Image courtesy of Senlian Hong, Wu Lab at Scripps Research

LA JOLLA, CA--Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes.

The new approach uses natural cancer-targeting immune cells, known as natural killer cells, that have been modified to selectively target lymphoma. As described in their study, published in the journal Angewandte Chemie, the modified natural killer cells brought about a dramatic reduction of lymphoma in a mouse.

"We found a way to achieve selectivity in targeting lymphoma cells, which is an important departure from existing therapies," says co-senior author Peng Wu, PhD, an associate professor in the Department of Molecular Medicine at Scripps Research.

Wu and his lab collaborated in the study with the lab of co-senior author James Paulson, PhD, the Cecil H. and Ida Green Professor and Chair of the Department of Molecular Medicine at Scripps Research.

More than 20,000 people in the United States die of lymphomas annually, while approximately 85,000 people are newly diagnosed. Most lymphomas arise from B cells, an important type of lymphocyte whose primary function is to make antibodies.

Some existing lymphoma treatments, including B-cell-killing antibodies and so-called CAR-T cell therapies, work by targeting B cells indiscriminately, largely wiping them out. However, this strategy brings many adverse side effects, including months of immunosuppression due to low antibody levels.

Wu, Paulson and their teams have developed a more specific approach using natural killer cells, which are immune cells that normally patrol the bloodstream and tissues, seeking and destroying virus-infected or cancerous cells. These immune-system warriors, also known as NK cells, are able to recognize certain tell-tale surface molecules that signify serious damage or malignancy within a cell; they can then kill that target cell through a variety of means, including by secreting proteins that punch holes in the cell's outer membrane.

Creating a super-powered NK cell

In the early 1990s, Canadian researchers developed a special type of NK cell, NK-92, from a patient with a rare NK-cell cancer. NK-92 cells are relatively easy to grow and multiply in the lab, compared with normal NK cells found in human blood.

The Canadian researchers and others have since shown that NK-92 cells are good at killing different kinds of cancerous cells, and can bring about dramatic results in some patients, with minimal side effects. NK-92MI cells, an easier-to-multiply version of NK-92 cells, are now being widely investigated for use against various cancers.

On their own, NK-92MI cells may not be ideal cancer-fighters, especially not for advanced malignancies, in part because they are dispersed throughout the body when infused into the bloodstream. In the new study, however, Wu and his team used chemistry techniques to modify NK-92MI cells to concentrate their cancer-fighting power against lymphoma.

Steering powerful cells where they're needed most

In an initial set of experiments, the Scripps Research scientists re-engineered NK-92MI cells to include a surface molecule that binds to a B-cell surface receptor called CD22, which is normally abundant on B-cell-derived lymphoma cells. Thus, in principle, the NK-92MI cells would selectively recognize cancerous B cells.

In cell-culture tests, the modification brought a big improvement in the NK cells' ability to kill lymphoma cells, and these killer cells did not harm healthy cells. In a mouse model of lymphoma, however, the strategy didn't work so well, apparently because the NK cells still did not go where they were needed.

"We found that after being injected, these NK cells tend to be found in the lungs and throughout the bloodstream--whereas in this mouse model and in human lymphoma patients, the lymphoma cells are mostly in the bone marrow," Wu says.

The team then added to their NK cells a new molecule called Sialyl-Lewis X, which made the cells gather in bone marrow amid the lymphoma cells. This led to a dramatic delay in the development of lymphoma in the mice. With this promising result, Wu and his lab now are continuing to develop this and related strategies for clinical use.

Wu and Paulson suspect that in general, adding homing molecules such as Sialyl-Lewis X to cell-based anticancer treatments enhances the cancer-killing power at the site of the cancer, and may be a key to these treatments' future success--particularly against solid tumors and other highly localized cancers.

Wu notes, too, that Sialyl-Lewis X, which made the NK-92MI cells gather in bone marrow, as well as the CD22-binding molecule that directed the cells to malignant B cells, are both sugar-like "glycan" molecules. Although such molecules are found on virtually all cells, and often have essential biological functions as well as crucial roles in disease, they are difficult to study and thus have been relatively neglected.

"People are only starting to appreciate the importance of glycans," says Senlian Hong, PhD, the first author of the study and a postdoctoral research associate in the Wu lab at Scripps Research.

Credit: 
Scripps Research Institute

Experimental vaccine can counter dangerous effects of synthetic cannabinoids

LA JOLLA, CA--Made in clandestine laboratories and sold widely across the United States, the diverse class of drugs known as synthetic cannabinoids presents a growing public health threat.

In a new study, Scripps Research scientists have devised a way to deactivate these designer drugs after they've been administered--offering a potential path for treating addiction and overdose.

The research appears today in the American Chemical Society's open access journal JACS Au, with findings from the laboratory of Kim Janda, PhD, the Ely R. Callaway, Jr. professor of chemistry at Scripps Research. Janda and his team developed a vaccine that was able to broadly counter the effects of synthetic cannabinoids in rodents, sequestering the drug molecules before they could interact with the central nervous system. Importantly, the approach worked in models that simulated smoking and vaping, which is how the drugs are most commonly used in real life.

"Synthetic cannabinoids are much more powerful and toxic than users often realize, and their rising prevalence has led to serious health issues among young people and adults," Janda says. "We found a way to negate the dangerous effects of these drugs, even when they're consumed in impure forms, as is often the case. Our hope is that this may one day help treat cannabinoid use disorders or accelerate recovery for people who overdosed."

Not to be confused with marijuana

Synthetic cannabinoids act on the same brain cell receptors as THC, the mind-altering ingredient in marijuana. However, they're man-made in a laboratory, with chemical structures that don't look anything like THC. Moreover, their actual effects can be unpredictable and, in some cases, fatal, Janda says.

The synthetic drugs are often sprayed on dried plant materials so they can be smoked, or sold as vaping liquids to be inhaled using e-cigarettes. Manufacturers tend to sell the products in colorful foil packages and plastic bottles under a wide variety of brand names, including Spice, K2, Joker, Black Mamba and hundreds of others.

Synthetic cannabinoids are also sometimes mixed with other dangerous drugs such as fentanyl, which can make them more deadly. Overdoses are on the upswing, as evidenced by calls to poison control centers.

"The drugs often called synthetic marijuana are, in reality, very different from marijuana," the American Association of Poison Control Centers says. "They contain powerful chemicals and can cause severe, life-threatening health effects: severe agitation and anxiety, nausea, vomiting, seizures and hallucinations. The drugs are made specifically to be abused. Like many other illegal drugs, synthetic marijuana is not tested for safety, and users don't know exactly what chemicals they are putting into their bodies."

Expanding on a proven method

For the study, Janda says first author Mingliang Lin, a graduate student, wanted to explore whether a vaccine could work against synthetic cannabinoids, just as they have shown to do against some other drugs of abuse. Janda already has developed vaccine-based approaches to combat heroin, fentanyl and cocaine.

As an addiction treatment, Janda believes vaccines provide benefits over other therapeutics, as they don't require taking a daily pill and can reduce the risk of an overdose if the user relapses.

The newest vaccine differs from Janda's previous work in that it's composed of multiple drug-like antigens that stimulate "broadly neutralizing" antibodies within the body, which disable many types of cannabinoids. This is key, as synthetic cannabinoids encompass a wide range of man-made chemicals.

In behavioral experiments involving mice, the team found that even when exposed to a large amount of the drug, the vaccine offered broad protection against the psychoactive effects. The team also developed a version of the vaccine that could be inhaled, which could offer greater convenience.

"This work provides a solid foundation for future therapeutic development against synthetic cannabinoid abuse," Janda says. "The ultimate goal is to provide prolonged protection for those who may be struggling with substance abuse."

Credit: 
Scripps Research Institute

New approach reveals structure and function of individual synapses

image: Multiphoton imaging in vivo provides measures of synaptic activity and function (left), while electron microscopy (right) performed on the same neuron provides structural information at the nanometer scale

Image: 
Max Planck Florida Institute for Neuroscience

A common analogy used to describe the brain is that it consists of tiny interconnected computers. Each one of these computers, or neurons, process and relay activity from thousands of other neurons, forming complex networks that allow us to perceive our surroundings, make decisions, and guide our actions. Communication between neurons occurs through tiny connections called synapses, and each neuron integrates the activity across these synapses to form a single output signal. However, not all synapses are created equal. Synapses converging onto an individual neuron differ in size, and size is correlated with strength: larger synapses are stronger and have a greater influence on a neuron's output than smaller synapses. But why are some synapses stronger than others, and how does this impact individual neurons processing incoming signals?

One well-known theory has suggested an answer. The Hebbian model for circuit development posits that the strength of a synapse between two neurons is determined by similarity in their activity. Synapses between neurons that are highly co-active become stronger than those that are less frequently co-active. This relationship provides a clear prediction for the diversity of synapse sizes present in mature neurons.  Large synapses would be formed with other neurons that have very similar response properties, and these synapses have a dominant role in determining the output of the neuron.  In contrast, small synapses would arise from neurons with less similar response properties and have less impact on the neuron's response. Although there is some evidence in support of this model, a direct test requires measuring the activity of individual synapses, their size, and their neuron's output signal, a combination that has been challenging to achieve with existing technologies.

Now, for the first time, an interdisciplinary team of scientists at the Max Planck Florida Institute for Neuroscience (MPFI) report the results of a novel approach that allowed them to achieve these measurements. Published in the journal Nature, their work challenges predictions of the Hebbian model, demonstrating that synapse size is not correlated with response similarity and suggests neural response properties reflect the total number of active synapses, both weak and strong.

Benjamin Scholl, Ph.D., a postdoctoral researcher in the Fitzpatrick lab at MPFI, was inspired to explore this question in the visual cortex, where he could take advantage of the fact that individual neurons exhibit a high degree of selectivity in their response to different features in the visual scene, such as the orientation of edges or the direction of a moving object. This phenomenon, termed feature selectivity, arises through the integration of thousands of synapses conveying different signals, but exactly how this occurs is unknown. "We aimed to test the hypothesis that the strong synapses have responses that closely match the neuron's feature selectivity, while the weak ones do not," explained Scholl, who is co-first author of the study. To test this hypothesis, the scientists utilized a light microscopy technique to visualize the activity of a population of synapses on individual neurons in real time. But this technique alone has a severe limitation--only synaptic activity can be observed, not their strength.

To measure synapse strength, a collaboration was formed with another team of scientists from the Electron Microscopy Core Facility at MPFI, led by Naomi Kamasawa, Ph.D. "Electron microscopy captures incredibly detailed images of a synapse, at the nanometer scale, allowing us to make precise measurements of their structure", explained Connon Thomas, co-first author of the work and an electron microscopy specialist. "These structural measurements tell us how strong each synapse is. By first examining synapse activity with light microscopy, then measuring the strength of those same exact synapses with electron microscopy, we knew we could answer this question". The combination of these techniques, termed Correlated Light and Electron Microscopy (CLEM), allowed the researchers to measure the function (feature selectivity) and structure (strength) of populations of synapses from several neurons.

In their initial results, the team found nothing unexpected: some synapses shared feature selectivity with the neuron, while others were different; some synapses were small (weak), while others were large (strong). But when these data were put together, the authors were surprised to find that both strong and weak synapses exhibited a wide variety of functional properties: there was no strict relationship as theorized. However, by examining the activity of the whole synaptic population, the researchers recognized that they had uncovered the likely synaptic basis for feature selectivity. "We observed a 'strength-in-numbers' phenomenon. Our data suggest that the feature selectivity of a neuron is derived from the total number of synapses activated, including strong and weak," described Scholl. "In fact, we found many more weak synapses driving feature selectivity, which suggests they could have a predominant influence". In support of this, the team observed that neighboring weaker synapses were more often co-active, which could even enhance their influence on the neuron.

These results challenge the prevailing theory that strong synapses are exclusively found between neurons with similar response properties and play the dominant role in determining a neuron's feature selectivity. Instead, selectivity appears to derive from the total numbers of synapses, suggesting that a synaptic democracy (akin to the popular vote) is most important. This still leaves open the question of why some synapses are stronger than others and studies are underway using these technologies to explore what other aspects of synaptic connections might be important. "Combining both structural and functional measurements of neurons provides a more holistic understanding of how our brains compute information" says Thomas. "The CLEM technique is allowing us to push the boundaries of what we know about fundamental workings of the brain." This work emphasizes the creative synergy that results from bringing together curiosity-driven scientists from different disciplines, enabling new insights into neural circuit organization that could not have been anticipated, and laying the foundation for tomorrow's advances in understanding disorders of brain function.

Credit: 
Max Planck Florida Institute for Neuroscience

Pandemic has severely disrupted sleep, increasing stress and medication use

image: Principal Investigator Rébecca Robillard, an Assistant Professor and co-director of the Sleep Laboratory of the School of Psychology at the University of Ottawa, and Head Scientist in the Sleep Research Unit at The Royal Institute of Mental Health Research.

Image: 
University of Ottawa

OTTAWA, ON _The COVID-19 pandemic is seriously affecting the sleep habits of half of those surveyed in a new study from The Royal and the University of Ottawa, leading to further stress and anxiety plus further dependence on sleep medication.

The global pandemic's impact on daily routines extends to the bed, according to 'Profiles of sleep changes during the COVID?19 pandemic: Demographic, behavioural and psychological factors'. The study was led by Principal Investigator Rébecca Robillard, an Assistant Professor and co-director of the Sleep Laboratory of the School of Psychology at the University of Ottawa, and Head Scientist in the Sleep Research Unit at The Royal Institute of Mental Health Research and published in the Journal of Sleep Research.

Dr. Robillard and her team, which was comprised of nearly two dozen scientists from across North America, conducted an online survey of 5,525 Canadian during the early phase of the COVID-19 pandemic. She walked us through some of the study's most important findings.

How has the pandemic affected our sleep?

RR: "The pandemic is having a diverse impact on people's sleep, with clinically meaningful sleep difficulties having undergone a sharp increase. We found that half of our participants showed signs of serious sleep problems during the pandemic. Specifically, we identified three different profiles of sleep changes: those who sleep more; those whose sleep schedule was pushed to later bed and wake-up times; and those who are getting less sleep than they did before the pandemic."

How is this significant change in sleep pattern affecting people's daily lives?

"Active changes people made on sleep-related behaviors during the pandemic not only affected sleep quality and quantity, but it also affected their psychological response to this unprecedented situation. Compared to those who are sleeping more, those who have later sleep schedules or shorter sleep cycles showed increased symptoms of insomnia and worsening symptoms of stress, anxiety and depression."

Were you able to identify any factors associated with this disruption of sleep patterns?

"Yes. New sleep difficulties seem to be disproportionately affecting women, those with families and family responsibilities, the employed, and individuals with chronic illnesses. It also impacted individuals with earlier wake-up times, higher stress levels, heavier alcohol use, and extra television exposure."

How have people coped?

"We have seen an increase in the use of sleeping medications during the pandemic. Considering the known risks for the development of tolerance with these medications, this may forecast a surge in more complex chronic insomnia cases in the long run."

Overall, what can be read into people's sleep patterns during the pandemic?

"The large scale of sleep changes in response to the pandemic highlights the need for more accessible, yet tailored interventions to address sleep problems. Sleep and mental health issues are something to be expected with the current circumstances, but we never expected to see it hit this level. It is important to intervene to address the unique phenomenon that we are facing right now."

What are some ways people can improve their sleep, even during the pandemic?

"Some simple habits can help you to get a good night sleep. They include:

Getting up at the same time each morning (even on weekends). Even if you fall asleep very late, you should still get up at the same time each morning;

Develop relaxing pre-sleep rituals such as reading;

Avoid caffeine and alcohol within six hours of bedtime, and don't smoke at bedtime;

Exercise regularly. Get vigorous exercise such as jogging either in the morning or afternoon. Get mild exercise, such as walking, two to three hours before bedtime.

Credit: 
University of Ottawa

Researchers identify neurons that control nausea-like responses in mice

image: GLP1R neurons (red) play a critical role in detecting toxins in blood vessels (green) and initiating the nausea response.

Image: 
Chuchu Zhang , Stephen Liberles

At some point, everyone experiences nausea. Whether it occurs after unwisely eating a week-old slice of pizza or as an accompaniment to a serious infection, that queasy, unsettling sensation centered around the stomach is a signal that something is amiss within the body and typically portends a bout of vomiting.

Most of the time, nausea is only temporary. But for some people, such as those on certain chemotherapy regimens, it can be severe, chronic and even life-threatening when it prevents patients from adhering to treatment.

In a new study published in Neuron, researchers at Harvard Medical School have now identified and characterized neurons that regulate nausea-like responses in mice. When these neurons are experimentally turned on, nausea-like responses can be activated regardless of exposure to nausea-triggering substances. Without these neurons, nausea-like responses to poisons are lost.

The results shed light on the sensation of nausea and present new targets for the design of improved, more precise antinausea medications.

"Everyone knows what nausea feels like, but it has been largely mysterious at a molecular and genetic level," said the study's corresponding author, Stephen Liberles, professor of cell biology in the Blavatnik Institute at HMS. "By identifying neuron types at the heart of this phenomenon, we can now investigate how it works and design better ways to control it in the future."

Liberles and colleagues, led by the study's first author, Chuchu Zhang, research fellow in cell biology at HMS, began their investigation of nausea by looking at a region of the brain called the area postrema.

Located in the brain stem, the area postrema has long been associated with vomiting and is one of the rare parts of the brain outside the blood-brain barrier that can monitor blood-borne chemicals. This is thought to allow the area postrema to detect harmful substances or danger signals in the bloodstream and act as an alarm bell when it does so.

Until now, the different types and functions of cells within the area postrema remained unclear. In their study, Zhang, Liberles and their team built an atlas of cell types, using single-nucleus RNA sequencing to characterize gene expression in thousands of individual area postrema cells from mice.

Fruity tricks

The atlas revealed that there were only a handful of different neuron types in the area postrema. Of particular interest were neurons that expressed GLP1R, a receptor protein on the cell surface that previous studies have linked to blood sugar and appetite control.

To probe whether these neurons play a role in nausea, the researchers had to first assess if mice were actually experiencing the sensation. They did so by adding cherry or grape flavoring to the animals' drinking water.

Then they gave the mice either an innocuous substance or one known to induce nausea. If a mouse felt malaise, it would quickly associate a fruit flavor with the negative sensation and avoid it, similar to how humans develop food aversions after eating something disagreeable.

The researchers tested several different substances, including lithium chloride and lipopolysaccharide, a toxin produced by bacteria associated with food poisoning. As expected, all tested substances led to strong flavor aversion in mice.

When GLP1R neurons were experimentally removed, however, mice stopped developing flavor aversions for most of the substances--an observation that suggested they no longer experienced malaise as normal.

The team also experimentally turned GLP1R neurons on. They found that mice with activated GLP1R neurons would acquire strong flavor aversions even when they had not been exposed to a nausea-inducing substance.

"We used a technique to activate these neurons, essentially tricking them into thinking there was a toxin present," Zhang said. "This led to conditioned flavor avoidance, which was strong evidence for a connection between these neurons and the nausea response."

Additional analyses revealed that GLP1R neurons connect to many other regions of the brain, including one called the parabrachial nucleus, which has been recognized as a hub for pain and aversion. This may be how area postrema neurons help induce conditioned flavor-aversion memories, Zhang said.

The team also found that GLP1R neurons expressed numerous other cell-surface receptors, such as the receptor GFRAL. Interestingly, removing this subset of neurons caused mice to stop developing flavor aversions for only lithium chloride and lipopolysaccharide.

This indicated a "division of labor" between area postrema neurons, with different neuron types responsible for detecting and raising the alarm for different substances.

Next generation

The study findings present a wealth of data to help scientists better understand nausea, how toxins or medicines trigger the sensation, and how it can be controlled to benefit patients, the authors said.

For example, the team found that certain neurons expressed a calcium-sensing receptor called CaSR. This receptor is a target for the drug cinacalcet, which is used to treat a hormonal imbalance in patients with chronic kidney disease and other conditions.

Nausea is a main side effect of this drug, and so the research team tested whether area postrema neurons were involved. Giving cinacalcet to mice led to flavor-aversion behaviors, which could be averted when GLP1R neurons were removed. This suggested that CaSR receptors may also play a role in nausea-like responses in area postrema neurons.

"Nausea is a very unpleasant sensation, and current antinausea drugs are not perfect," Zhang said. "Many people still experience nausea during cancer treatment, pregnancy and more, and so better understanding and treating nausea is a very important clinical need."

Numerous questions about these neurons and their role in nausea remain, the authors said. For example, it is still unclear which signals in the bloodstream area postrema neurons respond to. Their current working model is that toxins or medicines damage the body, triggering the release of chemicals into the bloodstream, which receptors on area postrema neurons detect.

In addition, the researchers note that their current work focused on excitatory neurons, which, when activated, go on to activate other neurons. Their atlas of area postrema cells identifies many other cell types, including inhibitory neurons, which dampen the activity of other neurons. The team is now investigating the function of these other cell types in the nausea response.

"Some of the most exciting and important discoveries in neuroscience have involved the identification of sensory receptors, both external and internal," said Liberles, who is a Howard Hughes Medical Institute Investigator. "While there has been a great deal of progress in understanding the neurons important for sensations like hunger, thirst and satiety, the neurons relevant for nausea have remained ill-defined."

"We still have a lot to do to understand how the sensation of nausea arises at the molecular, neural and cellular levels," Liberles added. "There are many next-generation questions enabled by these findings."

Credit: 
Harvard Medical School

Discriminatory policies threaten care for transgender, gender diverse individuals

WASHINGTON--The Endocrine Society and the Pediatric Endocrine Society oppose legislative efforts to block transgender and gender diverse individuals from accessing gender-affirming medical and surgical care, the two medical societies said in a joint policy perspective published in The Journal of Clinical Endocrinology & Metabolism.

In the past three years, legislators in 17 states have proposed more than two dozen bills barring medical and surgical treatments for transgender and gender diverse youth and adults. Many of these bills reflect widespread misinformation about the nature of evidence-based gender-affirming medical care.

"For young children experiencing feelings that their gender does not match the one assigned at birth, known as gender dysphoria, an initial intervention is likely to be a new haircut or clothing," said the manuscript's first author and Co-Chair of the Pediatric Endocrine Society's Transgender Special Interest Group Advocacy Subcommittee, Abby Walch, M.D., of the University of California San Francisco and Benioff Children's Hospitals in San Francisco, Calif. "The first course of action is to support the child in living as their affirmed gender identity and to provide mental health support as needed."

After transgender and gender diverse minors start puberty, prescribing hormones to suppress puberty is the recommended strategy if desired and if diagnostic and treatment criteria are met. This treatment, which is completely reversible, gives adolescents more time to explore their options.

Only reversible treatments are recommended for adolescents until they demonstrate the ability to provide informed consent and experience sustained feelings of gender dysphoria. Even then, gender-affirming hormone therapy to help individuals experience puberty in a way that matches their gender identity is partially reversible.

Three High Court judges in the United Kingdom ruled Dec. 1 that minors under the age of 16 likely could not give informed consent for pubertal suppression. Though it is likely to be challenged, this decision is a problematic development that could prevent transgender and gender diverse minors from obtaining the medical care they need.

"Considering transgender and gender diverse individuals face a disproportionately high risk of suicide and other health disparities, it is crucial that they have access to essential and often life-saving, gender-affirming care from well-informed health care professionals," said senior author and Co-Chair of the Endocrine Society's Transgender Research and Medicine Special Interest Group, Sean J. Iwamoto, M.D., of the University of Colorado School of Medicine and Rocky Mountain Regional VA Medical Center, both in Aurora, Colo. "Barring gender-affirming medical and surgical care for transgender and gender diverse individuals would force many to go through distressing and even traumatic experiences in life related to misgendering. No bill should criminalize physicians who provide the standard of care for this vulnerable population."

The course of gender-affirming treatment should be determined by patients and their health care providers, not by policymakers. Experts should be consulted regarding any policies governing treatment for transgender and gender diverse individuals, the authors wrote.

Credit: 
The Endocrine Society